SETD2 and cancer: Distinct subclonal SETD2 mutations occur in spatially separate regions of ccRCC, indicating selection for SETD2 inactivation, yet the advantage this mutation confers to cancer cells and/or the tumor microenvironment (TME) remains unclear [8].